{"id":"ivermectin-ivm","safety":{"commonSideEffects":[{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Arthralgia/myalgia"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Lymphadenopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ivermectin is an antiparasitic agent that selectively binds to invertebrate-specific glutamate-gated chloride ion channels, increasing chloride conductance and hyperpolarizing the cell membrane. This leads to paralysis and death of susceptible parasites including nematodes and arthropods. The drug has high selectivity for parasitic channels over mammalian GABA receptors, providing a favorable safety profile.","oneSentence":"Ivermectin binds to glutamate-gated chloride channels in parasitic organisms, causing paralysis and death of the parasite.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:35.181Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Onchocerciasis (river blindness)"},{"name":"Lymphatic filariasis"},{"name":"Strongyloidiasis"},{"name":"Scabies"},{"name":"Lice infestations"}]},"trialDetails":[{"nctId":"NCT04410406","phase":"PHASE3","title":"Moxidectin for LF, Cote d'Ivoire (DOLF)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-08-20","conditions":"Lymphatic Filariasis","enrollment":164},{"nctId":"NCT07286604","phase":"EARLY_PHASE1","title":"Ivermectin Repurposed for the Treatment of PKDL","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-03-02","conditions":"Post Kala Azar Dermal Leishmaniasis","enrollment":10},{"nctId":"NCT06070116","phase":"PHASE2","title":"Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-04-05","conditions":"Onchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular","enrollment":300},{"nctId":"NCT05124691","phase":"PHASE2, PHASE3","title":"Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms","status":"TERMINATED","sponsor":"Barcelona Institute for Global Health","startDate":"2022-01-20","conditions":"Helminthes; Infestation, Intestinal","enrollment":1001},{"nctId":"NCT06282315","phase":"PHASE3","title":"Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness","status":"RECRUITING","sponsor":"Insud Pharma","startDate":"2025-09-01","conditions":"Soil-Transmitted Helminths","enrollment":20000},{"nctId":"NCT03967054","phase":"PHASE3","title":"Repeat Ivermectin Mass Drug Administrations for MALaria Control II","status":"COMPLETED","sponsor":"Brian Foy","startDate":"2019-07-13","conditions":"Malaria","enrollment":4124},{"nctId":"NCT06497075","phase":"","title":"Co-administration of IVM and ALB in School-based Deworming in Uganda","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2024-07-01","conditions":"Helminthiasis, Intestinal Worms","enrollment":8767},{"nctId":"NCT04700423","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2021-03-01","conditions":"Trichuriasis, Ascariasis, Hookworm Infections","enrollment":536},{"nctId":"NCT04188301","phase":"PHASE2","title":"Safety and Efficacy of IDA for Onchocerciasis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-12-06","conditions":"Onchocerciasis","enrollment":154},{"nctId":"NCT06037876","phase":"PHASE3","title":"Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2023-10-09","conditions":"Trichuriasis","enrollment":161},{"nctId":"NCT03527732","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of IVM/ALB Co-administration","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2018-09-09","conditions":"Trichuriasis","enrollment":1673},{"nctId":"NCT05946642","phase":"PHASE3","title":"Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso","status":"UNKNOWN","sponsor":"Malaria Consortium","startDate":"2023-07-15","conditions":"Malaria","enrollment":13000},{"nctId":"NCT02974049","phase":"NA","title":"Lymphatic Filariasis (LF) in Ivory Coast","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2015-01","conditions":"Lymphatic Filariasis","enrollment":189},{"nctId":"NCT03576313","phase":"PHASE3","title":"Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-08-11","conditions":"Malaria","enrollment":4939},{"nctId":"NCT02616250","phase":"PHASE4","title":"MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-12","conditions":"Rosacea","enrollment":190},{"nctId":"NCT03517462","phase":"NA","title":"Ocular Changes After Ivermectin - (DOLF IVM/Oncho)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-08-06","conditions":"Onchocerciasis","enrollment":231},{"nctId":"NCT04343092","phase":"PHASE1","title":"Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management","status":"COMPLETED","sponsor":"University of Baghdad","startDate":"2020-04-18","conditions":"COVID 19","enrollment":16},{"nctId":"NCT04381884","phase":"PHASE2","title":"Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19","status":"COMPLETED","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2020-05-18","conditions":"COVID-19 Drug Treatment","enrollment":45},{"nctId":"NCT02845713","phase":"PHASE1","title":"Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2016-04-17","conditions":"Wuchereria Bancrofti Infection","enrollment":66},{"nctId":"NCT02078024","phase":"PHASE3","title":"Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2014-06","conditions":"Onchocerciasis","enrollment":375},{"nctId":"NCT01975441","phase":"PHASE2","title":"Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2014-05","conditions":"Lymphatic Filariasis","enrollment":182},{"nctId":"NCT03238131","phase":"PHASE3","title":"IVM Alone vs ALB + IVM Against Onchocerciasis","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2012-04","conditions":"Onchocerciasis","enrollment":272},{"nctId":"NCT03173742","phase":"PHASE1","title":"Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)","status":"COMPLETED","sponsor":"Insud Pharma","startDate":"2016-03","conditions":"Helminthiasis","enrollment":54},{"nctId":"NCT02568098","phase":"PHASE1","title":"Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-10","conditions":"Drug Combination, Pharmacokinetics, Healthy","enrollment":16},{"nctId":"NCT01593722","phase":"PHASE4","title":"Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"Loiasis","enrollment":155}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":815,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ivermectin"],"phase":"phase_3","status":"active","brandName":"ivermectin (IVM)","genericName":"ivermectin (IVM)","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivermectin binds to glutamate-gated chloride channels in parasitic organisms, causing paralysis and death of the parasite. Used for Onchocerciasis (river blindness), Lymphatic filariasis, Strongyloidiasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}